[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004108940A3 - Viral genome vectors - Google Patents

Viral genome vectors Download PDF

Info

Publication number
WO2004108940A3
WO2004108940A3 PCT/GB2004/002387 GB2004002387W WO2004108940A3 WO 2004108940 A3 WO2004108940 A3 WO 2004108940A3 GB 2004002387 W GB2004002387 W GB 2004002387W WO 2004108940 A3 WO2004108940 A3 WO 2004108940A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral genome
insertion site
genome vectors
relates
genome
Prior art date
Application number
PCT/GB2004/002387
Other languages
French (fr)
Other versions
WO2004108940A2 (en
Inventor
Michael Anthony Skinner
Michael Keith Howard
Joerg Schneider
Stephen Mark Laidlaw
Original Assignee
Oxxon Therapeutics Ltd
Inst Of Animal Health
Skinner Michael A
Michael Keith Howard
Joerg Schneider
Stephen Mark Laidlaw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxxon Therapeutics Ltd, Inst Of Animal Health, Skinner Michael A, Michael Keith Howard, Joerg Schneider, Stephen Mark Laidlaw filed Critical Oxxon Therapeutics Ltd
Publication of WO2004108940A2 publication Critical patent/WO2004108940A2/en
Publication of WO2004108940A3 publication Critical patent/WO2004108940A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a recombinant nucleic acid comprising a viral genome, said viral genome comprising an insertion of a heterologous nucleotide sequence into the viral genome, said insertion being located at a naturally occurring deletion or insertion site of said genome. In a preferred embodiment, the insertion site is an insertion site selected from table 2, or a homologue thereof. The invention also relates to viruses comprising said nucleic acids.
PCT/GB2004/002387 2003-06-04 2004-06-04 Viral genome vectors WO2004108940A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312803A GB2402391A (en) 2003-06-04 2003-06-04 Fowlpox recombinant genome
GB0312803.0 2003-06-04

Publications (2)

Publication Number Publication Date
WO2004108940A2 WO2004108940A2 (en) 2004-12-16
WO2004108940A3 true WO2004108940A3 (en) 2005-04-21

Family

ID=9959297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002387 WO2004108940A2 (en) 2003-06-04 2004-06-04 Viral genome vectors

Country Status (2)

Country Link
GB (1) GB2402391A (en)
WO (1) WO2004108940A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517292A1 (en) * 1991-05-27 1992-12-09 SOLVAY (Société Anonyme) Recombinant Avipox virus
WO1996040880A1 (en) * 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
GB2382578A (en) * 2001-11-30 2003-06-04 Isis Innovation Fowlpox-based vaccine
CA2467486A1 (en) * 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
IL164172A0 (en) * 2002-05-16 2005-12-18 Bavarian Nordic As Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517292A1 (en) * 1991-05-27 1992-12-09 SOLVAY (Société Anonyme) Recombinant Avipox virus
WO1996040880A1 (en) * 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AFONSO C L ET AL: "The genome of fowlpox virus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 8, April 2000 (2000-04-01), pages 3815 - 3831, XP002229418, ISSN: 0022-538X *
ANTOINE G ET AL: "The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses", VIROLOGY, vol. 244, no. 2, 10 May 1998 (1998-05-10), pages 365 - 396, XP002299585, ISSN: 0042-6822 *
BINNS M M ET AL: "ANALYSIS OF THE FOWLPOX VIRUS GENOME REGION CORRESPONDING TO THE VACCINIA VIRUS D6 TO A1 REGION LOCATION OF AND VARIATION IN NON-ESSENTIAL GENES IN POXVIRUSES", JOURNAL OF GENERAL VIROLOGY, vol. 71, no. 12, 1990, pages 2873 - 2882, XP009037559, ISSN: 0022-1317 *
BOULANGER DENISE ET AL: "Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategy.", JOURNAL OF VIROLOGICAL METHODS, vol. 106, no. 1, October 2002 (2002-10-01), pages 141 - 151, XP002299584, ISSN: 0166-0934 *
BOURSNELL M E G ET AL: "INSERTION OF THE FUSION GENE FROM NEWCASTLE DISEASE VIRUS INTO A NON-ESSENTIAL REGION IN THE TERMINAL REPEATS OF FOWLPOX VIRUS AND DEMONSTRATION OF PROTECTIVE IMMUNITY INDUCED BY THE RECOMBINANT", JOURNAL OF GENERAL VIROLOGY, vol. 71, no. 3, 1990, pages 621 - 628, XP009037597, ISSN: 0022-1317 *
LAIDLAW STEPHEN M ET AL: "Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses.", JOURNAL OF GENERAL VIROLOGY, vol. 85, no. 2, February 2004 (2004-02-01), pages 305 - 322, XP002299586, ISSN: 0022-1317 *
LAIDLAW STEPHEN M ET AL: "Fowlpox virus encodes nonessential homologs of cellular alpha-SNAP, PC-1, and an orphan human homolog of a secreted nematode protein", JOURNAL OF VIROLOGY, vol. 72, no. 8, August 1998 (1998-08-01), pages 6742 - 6751, XP002299583, ISSN: 0022-538X *
MEYER H ET AL: "MAPPING OF DELETIONS IN THE GENOME OF THE HIGHLY ATTENUATED VACCINIA VIRUS MVA AND THEIR INFUENCE ON VIRULENCE", JOURNAL OF GENERAL VIROLOGY, READING, BERKS, GB, vol. 72, 1991, pages 1031 - 1038, XP000952390, ISSN: 0022-1317 *
QINGZHONG Y ET AL: "Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F).", VACCINE. MAY 1994, vol. 12, no. 6, May 1994 (1994-05-01), pages 569 - 573, XP002299582, ISSN: 0264-410X *
SPEHNER D ET AL: "CONSTRUCTION OF FOWLPOX VIRUS VECTORS WITH INTERGENIC INSERTIONS: EXPRESSION OF THE BETA-GALACTOSIDASE GENE AND THE MEASLES VIRUS FUSION GENE", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 64, no. 2, 1 February 1990 (1990-02-01), pages 527 - 533, XP000749308, ISSN: 0022-538X *
SUTTER GERD ET AL: "Nonreplicating vaccinia vector efficiently expresses recombinant genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 89, no. 22, 1992, pages 10847 - 10851, XP002299581, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2004108940A2 (en) 2004-12-16
GB0312803D0 (en) 2003-07-09
GB2402391A (en) 2004-12-08

Similar Documents

Publication Publication Date Title
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
WO2003092592A3 (en) Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
WO2003092594A3 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
EP1098961A4 (en) Interferon inducing genetically engineered attenuated viruses
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
WO2004009768A3 (en) Viral vectors containing recombination sites
EP1256628A3 (en) Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2003087313A3 (en) Enhanced silk exsertion under stress
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
WO2001000234A3 (en) Methods and compositions for engineering of attenuated vaccines
WO2004087062A3 (en) Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
EP1845164A3 (en) Promoters for expression in modified vaccinia virus ankara
DE60040662D1 (en) VECTOR FOR INTEGRATING HETEROLOGIC SEQUENCES IN POXVIRUS GENOMES
WO2004108940A3 (en) Viral genome vectors
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
WO2002042450A8 (en) Sugarcane bacilliform virus promoters derived from isolates isolated from sugarcane cultivars
WO2000066743A3 (en) Viral expression vectors
WO2003033692A3 (en) Use of the adenoviral e2 late promoter
WO2001059108A3 (en) Inhibitors of apoptosis
IL139372A0 (en) Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof
WO2004048403A3 (en) Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
WO2003004600A3 (en) Improvement of viral uptake into cells and tissues
HUP0103871A2 (en) Recombinent celo virus and celo virus dna
EP1074624A4 (en) Attenuated chicken-pox virus oka strain gene 62 and method for identifying virus strain for attenuated live chicken-pox vaccine by using the gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase